To evaluate the reasons for changing to monotherapy with protease inhibitors, together with the proportion and reasons for the interruption to treatment, in patients who have been treated at some point with cobicistat-boosted darunavir (DRV/c). Outpatients in a tertiary hospital. Observational retrospective study to evaluate monotherapy with DRV/c (800 mg/150 mg) in adult patients with human immunodeficiency virus infection, from December 2014 to July 2022.
View Article and Find Full Text PDFEur J Hosp Pharm
March 2023
Objectives: This study aimed to describe the actions taken to implement a telepharmacy programme with home medication dispensing and informed delivery in an outpatient pharmaceutical care unit of a tertiary hospital, where approximately 5000 patients are treated per year. It also aimed to substantiate the applicability and benefits of the programme through analysing the findings and measuring patient satisfaction.
Methods: We identified the operational, logistical, technological and legal needs, as well as the need for training, information and coordination with the care team and patient associations.
Objective: To assess the quality of the labels for clinical trial samples through current regulations, and to analyze its potential correlation with the specific characteristics of each sample.
Method: A transversal multicenter study where the clinical trial samples from two third level hospitals were analyzed. The eleven items from Directive 2003/94/EC, as well as the name of the clinical trial and the dose on the label cover, were considered variables for labelling quality.
Objective: To study the incidence, risk factors, and treatment of hemorrhagic cystitis secondary to BK-virus reactivation (HC-BKV) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the pediatric population.
Methods: Case-control study in which all pediatric patients (0-18 years) who underwent allo-HSCT from September 2009 to January 2014 were followed.
Results: Twenty-nine patients underwent an allo-HSCT.
The dosage of antineoplastic drugs has historically been based on individualized prescription and preparation according to body surface area or patient´s weight. Lack of resources and increased assistance workload in the areas where chemotherapy is made, are leading to the development of new systems to optimize the processing without reducing safety. One of the strategies that has been proposed is the elaboration by dose banding.
View Article and Find Full Text PDFBackground And Objective: Pharmacogenetic studies have become in recent years a common practice in the development of new drugs, with the need to evaluate the information and readability of Informed Consent Forms(ICFs) to ensure compliance with the recommendations set by current legislation and expert groups.
Materials And Methods: Retrospective observational study that analyzes the content of ICFs received by participants of pharmacogenetic studies approved in a tertiary hospital. To evaluate the quality of the ICFs, a questionnaire of 42 questions was prepared (Table 1) with the elements that must contain the information given to subjects, while readability was assessed using different readability indices.